Showing 1591-1600 of 2813 results for "".
- GALDA Co-Director Explains Organization's Work and Impacthttps://modernaesthetics.com/news/galda-co-director-explains-organizations-work-and-impact/2475382/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- AB Chopra Epigenetics Launches With Plan to Revolutionize Longevityhttps://modernaesthetics.com/news/ab-chopra-epigenetics-launches-with-plan-to-revolutionize-longevity/2475380/Charles Rosier, co-founder of the Augustinus Bader skincare and biotech company, and Deepak Chopra, MD, announced the launch of AB Chopra Epigenetics, a revolutionary longevity platform that merges advanced artificial intelligence, epigenetic science, and consciousness-based healing to redefine t
- Dr. CI:Labo Presents New Clinical Data on Post-IPL Skincare for Asian Skin at IMCAS Asia 2025https://modernaesthetics.com/news/dr-cilabotm-presents-new-clinical-data-on-post-ipl-skincare-for-asian-skin-at-imcas-asia-2025/2475378/At IMCAS Asia 2025, Dr.CI:LABOTM presented new clinical findings demonstrating the efficacy of two of its skincare products—VC100 Essence Lotion EX and 377VC Radiance Serum—as adjuncts to Intense Pulsed Light (IPL) treatments in Asian patients. The data revealed that VC100 Esse
- Dr. Sebastian Cotofana Shares Unpublished Research Targeting Glabellar Lines with Neurotoxins at SCALEhttps://modernaesthetics.com/news/dr-sebastian-cotofana-shares-unpublished-research-targeting-glabellar-lines-with-neurotoxins-at-scale/2475377/The 20th anniversary of Music City Symposium for Cosmetic Advances and Laser Education (SCALE) was held from May 14 to 18 at the Grand Hyatt in Nashville, Tennessee. The agenda included an update on neurotoxin related to facial anatomy for improved aesthetic outcomes from Seb
- 2025 SCALE: Temple Filler Is Underappreciated But Crucialhttps://modernaesthetics.com/news/2025-scale-temple-filler-is-underappreciated-but-crucial/2475375/At the 20th anniversary of the Music City Symposium for Cosmetic Advances and Laser Education (SCALE), Vince Bertucci, MD, FRCPC, gave a lecture titled “Temple Fillers: Revisiting Current Dogma.” Key takeaway messages from the lecture included: THE TEMPLE’S ROLE IN
- New Collaboration Enhances Precision and Patient Engagement in Post-Weight-Loss Treatmentshttps://modernaesthetics.com/news/new-collaboration-enhances-precision-and-patient-engagement-in-post-weight-loss-treatments/2475376/MNML Aesthetics announced a partnership with ShapeScale to integrate 3D body imaging into its MNML Tone Method, a multi-modality body contouring protocol. The collaboration aims to enhance clinical precision and patient engagement in aesthetic practices, particularly in post-weight-loss body tran
- Cartessa Aesthetics Brings Aesthetic Devices to Canadahttps://modernaesthetics.com/news/cartessa-aesthetics-brings-aesthetic-devices-to-canada/2475372/Cartessa Aesthetics is expanding its Canadian portfolio with the launch of four new technologies, HELIX, TORO, EVERESSE, and ULTRAFORMER MPT, according to a press release from the manufacturer. The new devices are expected to give Canadian providers access to some of the most ad
- FDA Panel Urges Removal of Talc from Consumer Products Due to Cancer Linkhttps://modernaesthetics.com/news/fda-panel-urges-removal-of-talc-from-consumer-products-due-to-cancer-link/2475371/A U.S. Food and Drug Administration (FDA) advisory panel has reinforced longstanding concerns over the carcinogenic potential of talc, urging the agency to restrict its use in foods, drugs, and cosmetics. Citing more
- Revance Announces CEO Transitionhttps://modernaesthetics.com/news/revance-announces-ceo-transition/2475370/Revance announced a leadership transition last week as part of a long-term succession strategy following its integration with Crown Laboratories, according to a news release from the company. Founder and CEO of Crown Laboratories Jeff Bedard will assume the role of Executive Chai
- First Patient Dosed with GPX4 Modulator Targeting Pathologic Senescent Cellshttps://modernaesthetics.com/news/first-patient-dosed-with-gpx4-modulator-targeting-pathologic-senescent-cells/2475369/The first patient has been dosed with the lead drug candidate RLS-1496 in a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial, Rubedo Life Sciences, Inc., announced in a press release. The study marks the first time a glutathio